Renovascular hypertension is a recognized secondary potentially curable cause of hypertension since the work of Harry Goldblatt. Operative treatments for renal artery stenosis (RAS) have been offered for decades and percutaneous interventions have been widely available for 20 years. Stenting has largely obviated recurrence and modern techniques have contributed greatly to the safety of the procedure. Nevertheless, controversy abounds and prospective randomized trials have not successfully documented the value of intervention in patients with atherosclerotic RAS. The patient population has also changed remarkably. Whereas earlier patients with RAS were identified on clinical grounds, RAS is now commonly found serendipitously during angiography for other reasons. Whether or not these patients benefit from ‘drive by’ stenting is unknown. The practice may be hazardous and should be critically examined. A dialog and closer cooperation between cardiologists and nephrologists is warranted and organized programs should be formulated to address this problem.

Keywords:
Renal artery stenosis, Renal vascular disease, Ischemic nephropathy, Renal artery angioplasty, Renal artery stenting
1.
Cardiovascular Outcomes in Renal Atherosclerotic Lesions. www.clinicaltrials.gov.
2.
Bax L, Mali WP, Buskens E, STAR Study Group: The benefit of Stent placement and blood pressure and lipid-lowering for the prevention of progression of renal dysfunction caused by Atherosclerotic ostial stenosis of the renal artery. The STAR study: Rationale and study design. J Nephrol 2003;16:807–812.
3.
Angioplasty and stent for renal artery lesions. www.astral.bham.ac.uk.
4.
McAlister VC, Badovinac K: Transplantation in Canada: report of the Canadian Organ Replacement Register. Transplant Proc 2003;35:2428–2430.
5.
US Renal Data System, USRDS 2004 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2004.
6.
Gibson CM, Pinto DS, Murphy SA, Morrow DA, Hobbach HP, Wiviott SD, Giugliano RP, Cannon CP, Antman EM, Braunwald E, TIMI Study Group: Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. J Am Coll Cardiol 2003;42:1535–1543.
7.
French WJ, Wright RS: Renal insufficiency and worsened prognosis with STEMI. J Am Coll Cardiol 2003;42:1544–1546.
8.
Arant CB, Wessel TR, Olson MB, Merz CNB, Sopko G, Rogers WJ, Sharaf BL, Reis SE, Smtih KM, Johnson BD, Handberg E, Mankad S, Pepine CJ: Hemoglobin level is an independent predictor for adverse cardiovascular outcomes in women undergoing evaluation for chest pain. J Am Coll Cardiol 2004;43:2009–2014.
9.
Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, Salem DN, Levey AS, Sarnak MJ: Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol 2004;15:1307–1315.
10.
Weiner DE, Tighiouart H, Stark PC, Amin MG, MacLeod B, Griffith JL, Salem DN, Levey AS, Sarnak MJ: Kidney disease as a risk factor for recurrent cardiovascular disease and mortality. Am J Kidney Dis 2004;44:198–206.
11.
Knight EL, Rimm EB, Pai JK, Rexrode KM, Cannuscio CC, Manson JE, Stampfer MJ, Curhan GC: Kidney dysfunction, inflammation, and coronary events: a prospective study. J Am Soc Nephrol 2004;15:1897–1903.
12.
Textor SC: Ischemic nephropathy: where are we now? JASN 2004;15:1974–1982.
13.
Higashi Y, Sasaki S, Nakagawa K, Matsuura H, Oshima T, Chayama K: Endothelial function and oxidative stress in renovascular hypertension. N Engl J Med 2002;346:1954–1962.
14.
Epstein FH: Oxygen and renal metabolism. Kidney Int 1997;51:381–385.
15.
Zoccali C, Mallamaci F, Finocchiaro P: Atherosclerotic renal artery stenosis: epidemiology, cardiovascular outcomes, and clinical prediction rules. J Am Soc Nephrol 2002;13:S179–S183.
16.
Harding MB, Smith LR, Himmelstein SI, et al: Renal artery stenosis: prevalence and associated risk factors in patients undergoing routine cardiac catheterization. J Am Soc Nephrol 1992;2:1608–1616.
17.
MacDowall P, Kalra PA, et al: Risk of morbidity from renovascular disease in elderly patients with congestive cardiac failure. Lancet 1998;352:13–16.
18.
Scoble JE: The epidemiology and clinical manifestations of atherosclerotic renal disease; in Novick AC, Scoble J, Hamilton G (eds): Renal Vascular Disease. London, Saunders, 1996, pp 303–314.
19.
Krijnen P, van Jaarsveld BC, Steyerberg EW, Man in’t Veld AJ, Schalekamp MADH, Habbema JKF: A clinical prediction rule for renal artery stenosis. Ann Int Med 1998;129:705–711.
20.
Buller CE, Nogareda JG, Ramanathan K, Ricci DR, Djurdjev O, Tinckam KJ, Penn IM, Fox RS, Stevens LA, Duncan JA, Levin A: The profile of cardiac patients with renal artery stenosis. J Am Coll Cardiol 2004;43:1606–1613.
21.
Mailloux LU, Napolitano B, Bellucci AG, et al: Renal vascular disease causing end-stage renal disease, incidence, clinical correlates, and outcomes: a 20-year clinical experience. Am J Kidney Dis 1944;24:622–629.
22.
van Ampting JMA, Penne EL, Beek FJA, et al: Prevalence of atherosclerotic renal artery stenosis in patients staring dialysis. Nephrol Dial Tranplant 2003;18:1147–1151.
23.
Fatica RA, Port FK, Young EW: Incidence trends and mortality in end-stage renal disease attributed to renovascular disease in the United States. Am J Kidney Dis 2001;37:1184–1190.
24.
Svetky LP, Helms MJ, Dunnick NR, et al: Clinical characteristics useful in screening for renovascular disease. South Med J 1990;83:743–747.
25.
Crowley JJ, Santos RM, Peter RH, et al: Progression of renal artery stenosis in patients undergoing cardiac catheterization. Am Heart J 1998;136:913–918.
26.
Caps MT, Perissinotto C, Zierler RE, et al: Prospective study of atherosclerotic disease progression in the real artery. Circulation 1998;98:2866–2872.
27.
Caps MT, Zierler RE, Polissar NL, et al: Risk of atrophy in kidneys with atherosclerotic renal artier stenosis. Kidney Int 1998;53:753–742.
28.
Leertouwer TC, Pattynama PM, van den Berg-Huysmans A: Incidental renal artery stenosis in peripheral vascular disease: a case for treatment? Kidney Int 2001;59:1480–1483.
29.
Chabova V, Schirger A, Stanson AW, McKusick M, Textor SC: Outcomes of atherosclerotic renal artery stenosis managed without revascularization. Mayo Clin Proc 2000;75:437–444.
30.
Suresh M, Laboi P, Mamtora H, Kalra PR: Relationship of renal dysfunction to proximal arterial disease severity in atherosclerotic renovascular disease. Nephrol Dial Transplant 2000;15:631–636.
31.
Cheung CM, Wright JR, Shurrab AE, et al: Epidemiology of renal dysfunction and patient outcome in atherosclerotic renal artery occlusion. J Am Soc Nephrol 2002;13:149–157.
32.
Wright JR, Duggal A, Thomas R, Reeve R, Roberts IS, Kalra PA: Clinicopathological correlation in biopsy-proven atherosclerotic nephropathy: implications for renal functional outcome in atherosclerotic renovascular disease. Nephrol Dial Transplant 2001;16:765–770.
33.
Radermacher J, Chanvan A, Bleck J, et al: Use of Doppler unltrasonography to predict the outcome of therapy for renal-artery stenosis. N Engl J Med 2001;344:410–417.
34.
Murphy TP, Soares G, Kim M: Increase in utilization of percutaneous renal artery inteventions by Medicare beneficiaries 1996–2000. Am J Roentgenol 2004;183:561–568.
35.
Scolari F, Tardanico R, Zani R, Pola A, Viola BF, Movilli E, Maiorca R: Cholesterol crystal embolism: a recognizable cause of renal disease. Am J Kidney Dis 2000;36:1089–1109.
36.
Textor SC, Novick A, Tarazi RC, Kilmas V, Vidt DG, Pohl M: Critical perfusion pressure for renal function in patients with bilateral atherosclerotic renal vascular disease. Ann Intern Med 1985;102:309–314.
37.
Gross CM, Kramer J, Weingartner O, Uhlich F, Luft FC, Waigand J, Dietz R: Determination of renal arterial stenosis severity: comparison of pressure gradient and vessel diameter. Radiology 2001;220:751–756.
38.
Chatziioannou A, Mourikis D, Agroyannis B, Katsenis K, Pneumaticos S, Antoniou A, Dimakakos P, Vlachos L: Renal artery stenting for renal insufficiency in solitary kidney in 26 patients. Eur J Vasc Endovasc Surg 2002;23:49–51.
39.
Greco BA, Breyer JA: The natural history of renal artery stenosis: who should be evaluated for suspected ischemic nephropathy? Semin Nephrol 1996;16:2–11.
40.
Textor SC: ACE inhibitors in renovascular hypertension. Cardiovasc Drugs Ther 1990;4:229–235.
41.
Losito A, Gaburri M, Errico R, Parente B, Cao PG: Survival of patients with renovascular disease and ACE inhibition. Clin Nephrol 1999;52:339–343.
42.
Isles CG, Robertson S, Hill D: Management of renovascular disease: a review of renal artery stenting in ten studies. Q J Med 1999;92:159–167.
43.
Dorros G, Jaff M, Mathiak L, He T: Multicenter registry participants. Multicenter Palmaz stent renal artery stenosis revascularization registry report: four-year follow-up of 1,058 successful patients. Catheterization Cardiovasc Intervention 2002;55:182–188.
44.
Textor SC: Revascularization in atherosclerotic renal artery disease. Kidney Int 1998;53:799–811.
45.
Connolly JO, Higgins RM, Walters HL, Mackie ADR, Drury PL, Hendry BM, Scoble JE: Presentation, clinical features and outcome in different patterns of atherosclerotic renovascular disease. Q J Med 1994;87:413–421.
46.
Mikhail A, Scoble JE: Progressive renal dysfunction despite successful renal artery angioplasty in a single kidney. Lancet 1997;349:926.
47.
Hallett JW, Textor SC, Kos PB, Nicpon G, Bower TC, Cherry KJ, Glovicski P, Pairolero PC: Advanced renovascular hypertension and renal insufficiency: trends in medical comorbidity and surgical approach from 1970 to 1993. J Vasc Surg 1995;21:750–759.
48.
van Jaarsveld BC, Krijnen P, Pieterman H, Derkx FH, Deinum J, Postma CT, Dees A, Woittiez AJ, Bartelink AK, Man in ‘t Veld AJ, Schalekamp MA: The effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis. Dutch Renal Artery Stenosis Intervention Cooperative Study Group. N Engl J Med 2000;342:1007–1014.
49.
Plouin PF, Chatellier G, Darne B, Raynaud A: Blood pressure outcome of angioplasty in atherosclerotic renal artery stenosis: a randomized trial. Essai Multicentrique Medicaments vs. Angioplastie (EMMA) Study Group. Hypertension 1998;31:823–829.
50.
Webster J, Marshall F, Abdalla M, Dominiczak A, Edwards R, Isles CG, Loose H, Main J, Padfield P, Russell IT, Walker B, Watson M, Wilkinson R: Randomised comparison of percutaneous angioplasty vs. continued medical therapy for hypertensive patients with atheromatous renal artery stenosis. Scottish and Newcastle Renal Artery Stenosis Collaborative Group. J Hum Hypertens 1998;12:329–335.
51.
Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, Ruff SM, Zahedi K, Shao M, Bean J, Mori K, Barasch J, Devarajan P: Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005;365:1231–1238.
52.
Vasbinder GB, Nelemans PJ, Kessels AG, Kroon AA, Maki JH, Leiner T, Beek FJ, Korst MB, Flobbe K, de Haan MW, van Zwam WH, Postma CT, Hunink MG, de Leeuw PW, van Engleshoven JM: Renal Artery Diagnostic Imaging Study in Hypertension (RADISH Study Group). Accuracy of computed tomograrphic angiography and magnetic resonance angiography for diagnosing renal artery stenosis. Ann Intern Med 2004;141:674–682.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.